|
|
|
|
LEADER |
02745nmm a2200277 u 4500 |
001 |
EB000634926 |
003 |
EBX01000000000000000488008 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
140122 ||| eng |
020 |
|
|
|a 9781592594740
|
100 |
1 |
|
|a Skolnick, Phil
|e [editor]
|
245 |
0 |
0 |
|a Antidepressants
|h Elektronische Ressource
|b New Pharmacological Strategies
|c edited by Phil Skolnick
|
250 |
|
|
|a 1st ed. 1997
|
260 |
|
|
|a Totowa, NJ
|b Humana
|c 1997, 1997
|
300 |
|
|
|a X, 257 p
|b online resource
|
505 |
0 |
|
|a 1 Strategies to Optimize the Antidepressant Action of Selective Serotonin Reuptake Inhibitors -- 2 Antidepressant Properties of Specific Serotonin-Noradrenaline Reuptake Inhibitors -- 3 5-HT-Moduline: Novel Therapeutic Strategy for Antidepressant Action -- 4 Reversible Inhibitors of Monoamine Oxidase A (RIMAs): Where Can We Go from Here? -- 5 Calcium Channel Antagonists in Mood Disorders -- 6 Functional NMDA Antagonists: A New Class of Antidepressant Agents -- 7 Is an Adaptation of NMDA Receptors an Obligatory Step in Antidepressant Action? -- 8 NMDA Receptors and Affective Disorders -- 9 The Potential Contribution of Sigma Receptors to Antidepressant Actions -- 10 A Role for CREB in Antidepressant Action -- 11 Antidepressants: Beyond the Synapse -- 12 Animal Models to Detect Antidepressants: Are New Strategies Necessary to Detect New Agents? -- 13 Molecular Strategies to Novel Antidepressant Discovery
|
653 |
|
|
|a Neuroscience
|
653 |
|
|
|a Neurosciences
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
490 |
0 |
|
|a Contemporary Neuroscience
|
028 |
5 |
0 |
|a 10.1007/978-1-59259-474-0
|
856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-59259-474-0?nosfx=y
|x Verlag
|3 Volltext
|
082 |
0 |
|
|a 612.8
|
520 |
|
|
|a In Antidepressants: Current Trends and Future Directions, leading-edge investigators distill the dramatic recent advances in our understanding of the mechanisms responsible for antidepressant action. The authoritative contributors offer strategies to improve current therapies grounded on biogenic amine-based concepts. By departing from traditional strategies, the authors offer alternatives to therapies that often work too slowly or not at all, and suggest how the many recent advances in molecular biology and genetics might best be exploited in the design of optimal new therapies. Antidepressants: Current Trends and Future Directions summarizes novel concepts of antidepressant therapy that attempt to exploit provocative new insights from the laboratory to improve current, biogenic amine-based therapies. Readers will find the book an exceptional resource in opening the door to the development of newer and more effective antidepressant therapies
|